Cargando…

Pretreatment anti-thyroid autoantibodies indicate increased risk for thyroid autoimmunity secondary to alemtuzumab: A prospective cohort study

BACKGROUND: Alemtuzumab is approved for the treatment of active relapsing-remitting multiple sclerosis (RRMS). Alemtuzumab-related secondary autoimmune disorders (sAID) are common, with thyroid sAID being the most frequent, and fundamentally affect the risk-benefit ratio. Therefore, biomarkers indic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruck, Tobias, Schulte-Mecklenbeck, Andreas, Pfeuffer, Steffen, Heming, Michael, Klotz, Luisa, Windhagen, Susanne, Kleinschnitz, Christoph, Gross, Catharina C., Wiendl, Heinz, Meuth, Sven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	Research paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711888/ https://www.ncbi.nlm.nih.gov/pubmed/31371192 http://dx.doi.org/10.1016/j.ebiom.2019.07.062

Ejemplares similares

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells
por: Ruck, Tobias, et al.
Publicado: (2018)

ALAIN01—Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential
por: Ruck, Tobias, et al.
Publicado: (2016)

Alemtuzumab therapy changes immunoglobulin levels in peripheral blood and CSF
por: Möhn, Nora, et al.
Publicado: (2019)

Alemtuzumab treatment alters circulating innate immune cells in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2016)

Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity
por: Ruck, Tobias, et al.
Publicado: (2022)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis
por: Keller, Christian W., et al.
Publicado: (2019)

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis—A Longitudinal Observational Study
por: Riepl, Ester, et al.
Publicado: (2018)

Anti-thyroid autoantibodies as biomarkers for alemtuzumab associated thyroid autoimmunity
por: Reindl, Markus
Publicado: (2019)

Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond
por: Ruck, Tobias, et al.
Publicado: (2015)

Long-term efficacy of alemtuzumab in polymyositis
por: Ruck, Tobias, et al.
Publicado: (2015)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Signatures of immune reprogramming in anti-CD52 therapy of MS: markers for risk stratification and treatment response
por: Bierhansl, Laura, et al.
Publicado: (2019)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Amyotrophic lateral sclerosis patients show increased peripheral and intrathecal T-cell activation
por: Rolfes, Leoni, et al.
Publicado: (2021)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Alemtuzumab-Induced Autoimmune Thyroid Dysfunction
por: Ragavan, Sharanniyan, et al.
Publicado: (2022)

Immune Cell Profiling of the Cerebrospinal Fluid Provides Pathogenetic Insights Into Inflammatory Neuropathies
por: Heming, Michael, et al.
Publicado: (2019)

Alemtuzumab in Multiple Sclerosis: Short- and Long-Term Effects of Immunodepletion on the Peripheral Treg Compartment
por: Haas, Jürgen, et al.
Publicado: (2019)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Natural Killer Cells Are Present in Rag1(−/−) Mice and Promote Tissue Damage During the Acute Phase of Ischemic Stroke
por: Rolfes, Leoni, et al.
Publicado: (2021)

Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies
por: Dayan, Colin M., et al.
Publicado: (2023)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Autoimmunity complicating SARS-CoV-2 infection in selective IgA-deficiency
por: Pfeuffer, Steffen, et al.
Publicado: (2020)

Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis
por: Alamo, Angela, et al.
Publicado: (2019)

Thyroid Autoimmunity Following Alemtuzumab Treatment in Multiple Sclerosis Patients
por: Kazakou, Paraskevi, et al.
Publicado: (2021)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Dimethyl fumarate treatment alters circulating T helper cell subsets in multiple sclerosis
por: Gross, Catharina C., et al.
Publicado: (2015)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Vitamin D Status and Thyroid Autoantibodies in Autoimmune Thyroiditis
por: Koehler, Viktoria F., et al.
Publicado: (2019)

High anti-JCPyV serum titers coincide with high CSF cell counts in RRMS patients
por: Schneider-Hohendorf, Tilman, et al.
Publicado: (2020)

Contactin-associated protein 2 autoantibodies can be associated with multifocal motor-like neuropathy: a case report
por: Müller-Miny, Louisa, et al.
Publicado: (2023)

Onconeural antigen spreading in paraneoplastic neurological disease due to small cell lung cancer
por: Dik, Andre, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u2u72c1v6rk5s2jaano1h5jm50